Clinical Trial Update: Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic HR+/HER2- breast cancer (completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Vinorelbine (Vinorelbine)

Snippet

Sponsor: Johannes Gutenberg University Mainz | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED